Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Research Article

Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events?

Author(s): Mohamed Ben-Eltriki*, Manik Chhabra, Alan Cassels and James M. Wright

Volume 19, Issue 2, 2024

Published on: 15 August, 2023

Page: [244 - 247] Pages: 4

DOI: 10.2174/1574886318666230726124540

open access plus

conference banner
Abstract

Background: Proton pump inhibitors (PPIs) are one of the most used classes of drugs. For most indications, PPIs are only recommended up to 8 weeks duration. However, PPI use continues to expand. Regular and prolonged use of PPIs should be avoided because of the risk of adverse events.

Objectives: The main objective of this study was to (1) investigate the extent of PPI usage in people aged 65 or older in the province of British Columbia (BC), Canada, (2) provide an overview of the harms associated with the long-term use of PPIs.

Methods: We examined utilization trends of the PPIs in BC since the year 2009 using PharmaNet, BC’s medication dispensing database where the information is accessible to community pharmacists. We performed a comprehensive literature search for relevant reviews reporting harms associated with long-term use of PPIs. A search was conducted from January 2014 to June 2022.

Results: Between 2000 and 2018 BC’s population grew by 20%, but the use of PPIs escalated to 257%. Of these older British Columbians, 62% had a cumulative exposure exceeding 2 years and 42% exceeded 5 years. This is alarming because the recommended treatment duration is 4-12 weeks for common indications including reflux esophagitis, and duodenal and gastric ulcers. Only 13.5% were dispensed PPIs for 90 days or less. Patients on long-term PPI therapy should be reassessed. Adverse events of PPI use are common among older adults. We identified over 217 systematic reviews published during the last 8 years of specific harms associated with long-term daily usage of PPIs. These harms include increased risks of death, cardiovascular disease, acute renal injury, chronic kidney disease, dementia, fractures, hypomagnesemia, iron deficiency, vitamin B12 deficiency, enteric infection (including C. difficile), pneumonia, and neoplasia (gastric cancer, carcinoids, and colon cancer), and drug interactions.

Conclusion: This study revealed a high prevalence of PPI use among elderly populations in BC, Canada. The overutilization of PPIs is often a result of failure to re-evaluate the need for continuation of therapy. Published studies identified signals of serious harm from long-term PPI exposure. Healthcare providers with patients can reverse the relentless expansion of long-term PPI exposure by discussing the expected benefits and potential harms.

Keywords: Proton pump inhibitors, elderly patients, long-term adverse events, chronic kidney disease, dementia, fractures.

Graphical Abstract
[1]
Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil 2018; 24(2): 182-96.
[http://dx.doi.org/10.5056/jnm18001] [PMID: 29605975]
[2]
Ali Khan M, Howden CW. The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. Gastroenterol Hepatol (N Y) 2018; 14(3): 169-75.
[PMID: 29928161]
[3]
Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3): S5.
[4]
Triadafilopoulos G, Friedland S. Precision care for Barrett’s esophagus. Transl Gastroenterol Hepatol 2018; 3: 67.
[http://dx.doi.org/10.21037/tgh.2018.09.10] [PMID: 30363757]
[5]
Narayanan M, Reddy KM, Marsicano E. Peptic Ulcer Disease and Helicobacter pylori infection. Mo Med 2018; 115(3): 219-24.
[PMID: 30228726]
[6]
Calabrese C, Fabbri A, Febo GD. Long-term management of gerd in the elderly with pantoprazole. Clin Interv Aging 2007; 2(1): 85-92.
[http://dx.doi.org/10.2147/ciia.2007.2.1.85] [PMID: 18044079]
[7]
Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: A population-based study. BMC Gastroenterol 2022; 22(1): 58.
[http://dx.doi.org/10.1186/s12876-022-02130-2] [PMID: 35144540]
[8]
Runge TM, Abrams JA, Shaheen NJ. Epidemiology of barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 2015; 44(2): 203-31.
[http://dx.doi.org/10.1016/j.gtc.2015.02.001] [PMID: 26021191]
[9]
Kuipers EJ. PPIs for prevention and treatment of peptic ulcer. Lancet Gastroenterol Hepatol 2018; 3(4): 214-5.
[http://dx.doi.org/10.1016/S2468-1253(18)30047-5] [PMID: 29475805]
[10]
Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician 2017; 63(5): 354-64.
[PMID: 28500192]
[11]
Rababa M, Rababa’h A. The inappropriate use of proton pump inhibitors and its associated factors among community-dwelling older adults. Heliyon 2021; 7(7): e07595.
[http://dx.doi.org/10.1016/j.heliyon.2021.e07595]
[12]
Ben-Eltriki M, Green CJ, Maclure M, Musini V, Bassett KL, Wright JM. Do proton pump inhibitors increase mortality? A systematic review and in‐depth analysis of the evidence. Pharmacol Res Perspect 2020; 8(5): e00651.
[http://dx.doi.org/10.1002/prp2.651] [PMID: 32996701]
[13]
Batchelor R, Gilmartin JFM, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J Gastroenterol Hepatol 2017; 32(8): 1426-35.
[http://dx.doi.org/10.1111/jgh.13750] [PMID: 28128476]
[14]
Dagli RJ, Sharma A. Polypharmacy: A global risk factor for elderly people. J Int Oral Health 2014; 6(6): i-ii.
[PMID: 25628499]
[15]
Sharma R, Chhabra M, Vidyasagar K, Rashid M, Fialova D, Bhagavathula AS. Potentially inappropriate medication use in older hospitalized patients with type 2 diabetes: A cross-sectional study. Pharmacy 2020; 8(4): 219.
[http://dx.doi.org/10.3390/pharmacy8040219] [PMID: 33212819]
[16]
Bhagavathula AS, Vidyasagar K, Chhabra M, et al. Prevalence of polypharmacy, hyperpolypharmacy and potentially inappropriate medication use in older adults in india: A systematic review and meta-analysis. Front Pharmacol 2021; 12: 685518.
[http://dx.doi.org/10.3389/fphar.2021.685518] [PMID: 34093207]
[17]
Gastroenterology cao. choosing wisely canada. gastroenterology– five things physicians and patients should question. Last updated 2021. Available from: https://choosingwiselycanada.org/recommendation/gastroenterology/ accessed on November 2021
[18]
Benmassaoud A, McDonald EG, Lee TC. Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. CMAJ 2016; 188(9): 657-62.
[http://dx.doi.org/10.1503/cmaj.150570] [PMID: 26598371]
[19]
Boster J, Lowry LE, Bezzant ML, Kuiper B, Surry L. Reducing the inappropriate use of proton pump inhibitors in an internal medicine residency clinic. Cureus 2020; 12(1): e6609.
[http://dx.doi.org/10.7759/cureus.6609] [PMID: 32064190]
[20]
Wong SL, Sulaiman N, Ng KM, Lee ZY. Pharmacist-structured review of proton pump inhibitor utilisation in primary care: A non-randomised control study. Malays Fam Physician 2021; 16(3): 87-96.
[http://dx.doi.org/10.51866/oa1153] [PMID: 34938396]
[21]
Therapeutics Initiative Trends in utilization of proton pump inhibitors in British Columbia Therapeutics Letter 2019; Feb- Mar(118): 1-2.https://ti.ubc.ca/letter118
[22]
Therapeutics Initiative. Serious harms with long-term PPI use in older adultsTherapeutics Letter 2020; Mar-Apr(126): 1-2.https://ti.ubc.ca/letter126

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy